Clinical Trials Logo

Ovarian Epithelial Carcinoma clinical trials

View clinical trials related to Ovarian Epithelial Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01536743 Completed - Clinical trials for Ovarian Epithelial Carcinoma

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Start date: December 15, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to obtain an estimate of the biochemical response rate as determined by CA125 response using the Gynecologic Cancer Intergroup (GCIG) response criteria of PD0332991 in patients with recurrent ovarian epithelial carcinoma. CA125 response is defined as ≥ 50% decrease from the baseline CA125 level and confirmed ≥ 21 days after initial evaluation (baseline is defined as the higher value of 2 pre-treatment CA125 assessments).